Predictive monitoring and therapeutic immune biomarkers in the management of clinical complications of COVID-19

被引：21

作者：

Fouladseresht, Hamed ^{[1
]}

Doroudchi, Mehrnoosh ^{[2
]}

Rokhtabnak, Najmeh ^{[3
]}

Abdolrahimzadehfard, Hossein ^{[1
]}

Roudgari, Amir ^{[1
]}

Sabetian, Golnar ^{[1
]}

Paydar, Shahram ^{[1
]}

机构：

[1] Shiraz Univ Med Sci, Shahid Rajaee Emtiaz Trauma Hosp, Trauma Res Ctr, Shiraz, Iran

[2] Shiraz Univ Med Sci, Sch Med, Dept Immunol, Shiraz, Iran

[3] Shahid Bahonar Univ Kerman, Dept Biol, Fac Sci, Kerman, Iran

来源：

CYTOKINE & GROWTH FACTOR REVIEWS | 2021年 / 58卷

关键词：

COVID-19; Biomarker; Immunopathology; Cytokine storm; Lung; Complications; RESPIRATORY-DISTRESS-SYNDROME; SURFACTANT PROTEIN-D; SARS CORONAVIRUS; SPIKE PROTEIN; RESPONSES; INTERFERON; INHIBITION; NECROSIS; IGG; COV;

D O I：

10.1016/j.cytogfr.2020.10.002

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARSCoV-2), appears with a wide spectrum of mild-to-critical clinical complications. Many clinical and experimental findings suggest the role of inflammatory mechanisms in the immunopathology of COVID-19. Hence, cellular and molecular mediators of the immune system can be potential targets for predicting, monitoring, and treating the progressive complications of COVID-19. In this review, we assess the latest cellular and molecular data on the immunopathology of COVID-19 according to the pathological evidence (e.g., mucus and surfactants), dysregulations of proand anti-inflammatory mediators (e.g., cytokines and chemokines), and impairments of innate and acquired immune system functions (e.g., mononuclear cells, neutrophils and antibodies). Furthermore, we determine the significance of immune biomarkers for predicting, monitoring, and treating the progressive complications of COVID-19. We also discuss the clinical importance of recent immune biomarkers in COVID-19, and at the end of each section, recent clinical trials in immune biomarkers for COVID-19 are mentioned.

引用

页码：32 / 48

页数：17

共 159 条

[41] Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease [J].

Gabay, Cem ;

Fautrel, Bruno ;

Rech, Juergen ;

Spertini, Francois ;

Feist, Eugen ;

Koetter, Ina ;

Hachulla, Eric ;

Morel, Jacques ;

Schaeverbeke, Thierry ;

Hamidou, Mohamed A. ;

Martin, Thierry ;

Hellmich, Bernhard ;

Lamprecht, Peter ;

Schulze-Koops, Hendrik ;

Courvoisier, Delphine Sophie ;

Sleight, Andrew ;

Schiffrin, Eduardo Jorge .

ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (06) :840-847

[42]

Gao T., 2020, HIGHLY PATHOGENIC CO, DOI DOI 10.1101/2020.03.29.20041962

[43]

Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI [10.1016/j.ijantimicag.2020.105949, 10.1016/j.ijantimicag.2020.106063]

[44] Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure [J].

Giamarellos-Bourboulis, Evangelos J. ;

Netea, Mihai G. ;

Rovina, Nikoletta ;

Akinosoglou, Karolina ;

Antoniadou, Anastasia ;

Antonakos, Nikolaos ;

Damoraki, Georgia ;

Gkavogianni, Theologia ;

Adami, Maria-Evangelia ;

Katsaounou, Paraskevi ;

Ntaganou, Maria ;

Kyriakopoulou, Magdalini ;

Dimopoulos, George ;

Koutsodimitropoulos, Ioannis ;

Velissaris, Dimitrios ;

Koufargyris, Panagiotis ;

Karageorgos, Athanassios ;

Katrini, Konstantina ;

Lekakis, Vasileios ;

Lupse, Mihaela ;

Kotsaki, Antigone ;

Renieris, George ;

Theodoulou, Danai ;

Panou, Vassiliki ;

Koukaki, Evangelia ;

Koulouris, Nikolaos ;

Gogos, Charalambos ;

Koutsoukou, Antonia .

CELL HOST & MICROBE, 2020, 27 (06) :992-+

[45] Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis [J].

Gralinski, Lisa E. ;

Sheahan, Timothy P. ;

Morrison, Thomas E. ;

Menachery, Vineet D. ;

Jensen, Kara ;

Leist, Sarah R. ;

Whitmore, Alan ;

Heise, Mark T. ;

Baric, Ralph S. .

MBIO, 2018, 9 (05)

[46]

Guan WJ, 2020, EUR RESPIR J, V55, DOI [10.1183/13993003.00547-2020, 10.1371/journal.pone.0240308, 10.1183/13993003.00597-2020]

[47] Division of labor between lung dendritic cells and macrophages in the defense against pulmonary infections [J].

Guilliams, M. ;

Lambrecht, B. N. ;

Hammad, H. .

MUCOSAL IMMUNOLOGY, 2013, 6 (03) :464-473

[48] Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020 [J].

Haveri, Anu ;

Smura, Teemu ;

Kuivanen, Suvi ;

Osterlund, Pamela ;

Hepojoki, Jussi ;

Ikonen, Niina ;

Pitkapaasi, Marjaana ;

Blomqvist, Soile ;

Ronkko, Esa ;

Kantele, Anu ;

Strandin, Tomas ;

Kallio-Kokko, Hannimari ;

Mannonen, Laura ;

Lappalainen, Maija ;

Broas, Markku ;

Jiang, Miao ;

Siira, Lotta ;

Salminen, Mika ;

Puumalainen, Taneli ;

Sane, Jussi ;

Melin, Merit ;

Vapalahti, Olli ;

Savolainen-Kopra, Carita .

EUROSURVEILLANCE, 2020, 25 (11) :16-21

[49] Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis [J].

Henry, Brandon Michael ;

de Oliveira, Maria Helena Santos ;

Benoit, Stefanie ;

Plebani, Mario ;

Lippi, Giuseppe .

CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2020, 58 (07) :1021-1028

[50] Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [J].

Huang, Chaolin ;

Wang, Yeming ;

Li, Xingwang ;

Ren, Lili ;

Zhao, Jianping ;

Hu, Yi ;

Zhang, Li ;

Fan, Guohui ;

Xu, Jiuyang ;

Gu, Xiaoying ;

Cheng, Zhenshun ;

Yu, Ting ;

Xia, Jiaan ;

Wei, Yuan ;

Wu, Wenjuan ;

Xie, Xuelei ;

Yin, Wen ;

Li, Hui ;

Liu, Min ;

Xiao, Yan ;

Gao, Hong ;

Guo, Li ;

Xie, Jungang ;

Wang, Guangfa ;

Jiang, Rongmeng ;

Gao, Zhancheng ;

Jin, Qi ;

Wang, Jianwei ;

Cao, Bin .

LANCET, 2020, 395 (10223) :497-506

← 1 2 3 4 5 6 7 8 9 10 →